CAMT Stock Analysis: Camtek | NASDAQ
Semiconductor Equipment & Materials | NASDAQ, USA | Market Cap: 5.654m USD | 12M Return: 8.7% | IL0010952641 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 68.0M
EPS Trend: 93.1%
Qual. Beats: 1
Rev. Trend: 97.0%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Camtek Ltd. (NASDAQ: CAMT) is an Israeli-headquartered company that designs, manufactures, and sells inspection and metrology equipment for the semiconductor industry, with operations spanning the United States, China, Korea, Europe, and the rest of Asia Pacific. Founded in 1987 and based in Migdal HaEmek, the company sells to semiconductor manufacturers, OSATs (outsourced semiconductor assembly and test providers), integrated device manufacturers, and wafer-level packaging subcontractors. Its product portfolio includes the Hawk platform for advanced packaging, the Eagle family (G5, i/Plus, AP/Plus) for 2D and 3D inspection and metrology, the Golden Eagle for standard panel inspection, and the MicroProf line of wafer metrology and surface measurement tools used in 3D packaging, MEMS, sapphire, and LED applications.
The company operates within the Semiconductor Materials & Equipment sub-industry, a capital-equipment niche that supplies fabs and packaging facilities with tools used to detect defects and measure critical dimensions on wafers and finished chips. Camteks emphasis on advanced packaging and 3D inspection aligns with a broader industry shift toward chiplet architectures, heterogeneous integration, and high-bandwidth memory, all of which require increasingly sophisticated metrology at the packaging stage.
- Advanced packaging inspection orders surge on AI chip demand
- China revenue concentration raises export control and tariff risk
- HBM capacity expansion fuels metrology system sales growth
| Net Income: 37.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -11.41 > 1.0 |
| NWC/Revenue: 157.0% < 20% (prev 121.5%; Δ 35.49% < -1%) |
| CFO/TA 0.11 > 3% & CFO 141.9m > Net Income 37.7m |
| Net Debt (-130.9m) to EBITDA (55.6m): -2.35 < 3 |
| Current Ratio: 7.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.5m) vs 12m ago 4.45% < -2% |
| Gross Margin: 50.05% > 18% (prev 50.29%; Δ -0.24% > 0.5%) |
| Asset Turnover: 44.00% > 50% (prev 48.38%; Δ -4.38% > 0%) |
| Interest Coverage Ratio: 26.46 > 6 (EBIT TTM 43.8m / Interest Expense TTM 1.66m) |
| A: 0.60 (Total Current Assets 924.4m - Total Current Liabilities 125.3m) / Total Assets 1.34b |
| B: 0.33 (Retained Earnings 441.5m / Total Assets 1.34b) |
| C: 0.04 (EBIT TTM 43.8m / Avg Total Assets 1.16b) |
| D: 1.13 (Book Value of Equity 710.2m / Total Liabilities 628.9m) |
| Altman-Z'' = 6.43 = AAA |
| DSRI: 1.12 (Receivables 153.9m/127.8m, Revenue 509.0m/471.6m) |
| GMI: 1.00 (GM 50.29% / 50.05%) |
| AQI: 1.17 (AQ_t 0.26 / AQ_t-1 0.22) |
| SGI: 1.08 (Revenue 509.0m / 471.6m) |
| TATA: -0.08 (NI 37.7m - CFO 141.9m) / TA 1.34b) |
| Beneish M = -2.78 (Cap -4..+1) = A |
As of October 30, 2026, the stock is trading at USD 128.78 with a total of 390,807 shares traded. Over the past week, the price has changed by -3.24%, over one month by -9.70%, over three months by -8.05% and over the past year by +8.68%.
Current recommended Stop Loss: 116.90 (which is 9.2% or 1.4 ATR below the current price).
Camtek has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CAMT.
- StrongBuy: 5
- Buy: 2
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 172.8 | 34.2% |
P/E Trailing = 186.4
P/E Forward = 28.2486
P/S = 11.3292
P/B = 9.1054
P/EG = 2.0157
Revenue TTM = 509.0m USD
EBIT TTM = 43.8m USD
EBITDA TTM = 55.6m USD
Long Term Debt = 488.5m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 499.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 11.0m
Net Debt = -130.9m USD (calculated: Debt 499.5m - CCE 630.4m)
Enterprise Value = 5.52b USD (5.65b + Debt 499.5m - CCE 630.4m)
Interest Coverage Ratio = 26.46 (Ebit TTM 43.8m / Interest Expense TTM 1.66m)
EV/FCF = 105.4x (Enterprise Value 5.52b / FCF TTM 52.4m)
FCF Yield = 0.95% (FCF TTM 52.4m / Enterprise Value 5.52b)
FCF Margin = 10.30% (FCF TTM 52.4m / Revenue TTM 509.0m)
Net Margin = 7.40% (Net Income TTM 37.7m / Revenue TTM 509.0m)
Gross Margin = 50.05% ((Revenue TTM 509.0m - Cost of Revenue TTM 254.2m) / Revenue TTM)
Gross Margin QoQ = 50.06% (prev 50.08%)
Tobins Q-Ratio = 4.12 (Enterprise Value 5.52b / Total Assets 1.34b)
Interest Expense / Debt = 0.33% (Interest Expense 1.66m / Debt 499.5m)
Taxrate = 19.70% (9.24m / 46.9m)
NOPAT = 35.2m (EBIT 43.8m * (1 - 19.70%))
Current Ratio = 5.32 (Total Current Assets 924.4m / Total Current Liabilities 173.7m)
Debt / Equity = 0.70 (Debt 499.5m / totalStockholderEquity, last quarter 710.2m)
Debt / EBITDA = -2.35 (Net Debt -130.9m / EBITDA 55.6m)
Debt / FCF = -2.50 (Net Debt -130.9m / FCF TTM 52.4m)
Total Stockholder Equity = 646.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.26% (Net Income 37.7m / Total Assets 1.34b)
RoE = 5.82% (Net Income TTM 37.7m / Total Stockholder Equity 646.9m)
RoCE = 3.86% (EBIT 43.8m / Capital Employed (Equity 646.9m + L.T.Debt 488.5m))
RoIC = 2.96% (NOPAT 35.2m / Invested Capital 1.19b)
WACC = 11.90% (E(5.65b)/V(6.15b) * Re(12.93%) + D(499.5m)/V(6.15b) * Rd(0.33%) * (1-Tc(0.20)))
Discount Rate = 12.93% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: 31.40 | Cagr: 2.02%
[DCF] Terminal Value 61.09% ; FCFF base≈91.2m ; Y1≈80.0m ; Y5≈64.6m
[DCF] Fair Price = 16.89 (EV 657.4m - Net Debt -130.9m = Equity 788.3m / Shares 46.7m; r=11.90% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 93.07 | EPS CAGR: 21.29% | SUE: 4.0 | # QB: 1
Revenue Correlation: 96.99 | Revenue CAGR: 21.94% | SUE: 2.62 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.99 | Chg30d=+0.91% | Revisions=+64% | Analysts=10
EPS current Year (2026-12-31): EPS=3.63 | Chg30d=+0.39% | Revisions=+77% | GrowthEPS=+11.4% | GrowthRev=+20.0%
EPS next Year (2027-12-31): EPS=5.08 | Chg30d=+6.06% | Revisions=+80% | GrowthEPS=+39.8% | GrowthRev=+34.5%
[Analyst] Revisions Ratio: +86% (up=32, down=1)